-- SAMPLE BLOG POST INSERTION SCRIPT
-- RUN THIS IN SUPABASE SQL EDITOR

INSERT INTO public.blogs (
    title,
    slug,
    excerpt,
    content,
    cover_image,
    published,
    published_at,
    author_id, -- NULL uses "After Trials Team" default, or replace with a User UUID
    tags,
    seo_title,
    seo_description,
    read_time_minutes
) VALUES (
    'The Future of Decentralized Clinical Trials: Bridging the Gap in patient Access',
    'future-of-decentralized-clinical-trials',
    'Decentralized clinical trials (DCTs) are revolutionizing medical research by bringing the trial to the patient. Discover how remote monitoring, wearable tech, and virtual visits are increasing diversity and retention in modern studies.',
    
    -- MARKDOWN CONTENT BELOW
    '# The Shift to Patient-Centric Research

Clinical trials have traditionally been site-centric, requiring patients to travel to major medical centers for participation. This model often excludes diverse populations due to geographic, economic, and logistical barriers. **Decentralized Clinical Trials (DCTs)** represent a fundamental shift, leveraging technology to meet patients where they are.

## Why Decentralization Matters

The "site-less" or hybrid approach offers transformative benefits:

1.  **Increased Diversity**: By removing the need for frequent travel, trials can enroll participants from rural and underserved areas.
2.  **Higher Retention**: Reduced burden on patients leads to significantly lower dropout rates.
3.  **Real-World Data**: Wearables and sensors capture continuous data in a patient''s natural environment, offering richer insights than episodic clinic visits.

> "The future of clinical research is not about bringing the patient to the trial, but bringing the trial to the patient."

## Key Technologies Driving Change

The infrastructure for DCTs relies on a stack of integrated digital tools:

-   **eConsent**: Remote electronic informed consent allows patients to review and sign documents from home.
-   **Telemedicine**: Virtual visits replace routine check-ups, maintaining the investigator-patient conceptual link.
-   **RWD/RWE**: Real-world data integration from electronic health records (EHR) and claims data.
-   **Direct-to-Patient Logistics**: Shipping investigational medicinal products (IMP) directly to the participant''s home.

## Challenges and Considerations

While the promise is great, the implementation is complex. Data integrity, regulatory compliance across jurisdictions, and the "digital divide" among older populations remain critical hurdles that sponsors and CROs must address.

### The Road Ahead

As regulatory bodies like the FDA and EMA continue to issue guidance on decentralized methods, we expect DCTs to become the standard, not the exception. For physicians and researchers, adapting to this digital-first ecosystem is no longer optional—it is essential for the future of evidence-based medicine.
',
    -- END OF MARKDOWN CONTENT

    -- COVER IMAGE (Replace with your own uploaded image URL if you prefer)
    'https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?auto=format&fit=crop&w=1200&q=80',
    
    true,   -- Published status
    now(),  -- Published at current timestamp
    NULL,   -- Author ID (NULL defaults to "After Trials Team" in our UI logic)
    ARRAY['Clinical Trials', 'Digital Health', 'Innovation', 'Research'], -- Tags
    'Future of Decentralized Clinical Trials | After Trials Insights', -- SEO Title (<60 chars optimal)
    'Explore how decentralized clinical trials (DCTs) use technology to improve patient access, diversity, and retention in medical research.', -- SEO Description (<160 chars optimal)
    5 -- Estimated read time
);
